ITI Pharma and Healthcare Fund Direct Growth
NAV ₹20.5606 on 13 November 2026
AMFI name: ITI Pharma and Healthcare Fund - Direct Plan - Growth Option · Scheme code 149268 · ISIN INF00XX01BO9
Returns
To 13 November 2026. Up to 1 year: total change. 3 and 5 years: compound return a year.
| Period | This fund | NIFTY HEALTHCARE INDEX TRI | Category median |
|---|---|---|---|
| 1M | +9.38% | +8.67% | +5.71% |
| 6M | +12.34% | +12.84% | +7.79% |
| 1Y | +16.80% | +38.92% | +4.11% |
| 3Y | +20.53% | +28.05% | +14.35% |
| 5Y | +15.45% | - | +12.25% |
Benchmark: NIFTY HEALTHCARE INDEX TRI (total return index), measured over the same dates.
Category median: the middle return among Direct plans (Growth option) in AMFI's “Equity Scheme - Sectoral/ Thematic” category, up to 174 funds with clean data. Ranks are under “Rank among peers”.
Risk
From daily NAVs. Alpha, beta and capture are measured against NIFTY HEALTHCARE INDEX TRI.
- Volatility
- 14.41%
- Annualised, 3 years
- Max drawdown
- -17.07%
- Worst fall from a peak, 3 years
- Sharpe ratio
- 1.01
- Return above the risk-free rate per unit of volatility, 3 years
- Sortino ratio
- 1.37
- Like Sharpe, counting only falls, 3 years
- Alpha
- +2.09%
- Return a year beyond what beta explains, 3 years
- Beta
- 0.58
- 1.00 moves in step with the benchmark, 3 years
- Upside capture
- 59%
- Share of the benchmark's rises captured, 3 years
- Downside capture
- 96%
- Share of the benchmark's falls taken (lower is better), 3 years
Every 3-year holding period
Compound return a year for each 3-year window in the NAV history we hold. Less sensitive to the end date than a single 3-year figure.
Rank among peers
Direct plans, Growth option, in AMFI's “Equity Scheme - Sectoral/ Thematic” category. Each rank counts only the peers that have that figure.
| Rank | Scheme Name | 3Y Return | 1Y Return | Sharpe | Direct TER | AUM |
|---|---|---|---|---|---|---|
| #1 | Nippon India Mutual Fund | +46.52% | +60.64% | 1.07 | 1.06% | ₹1,100 Cr |
| #2 | HDFC Mutual Fund | +33.64% | +20.34% | 1.07 | 0.89% | ₹11,128 Cr |
| #3 | HDFC Mutual Fund | +31.28% | +31.60% | 1.76 | 1.03% | ₹3,128 Cr |
| #4 | SBI Mutual Fund | +25.42% | +26.07% | 1.47 | 0.76% | ₹5,565 Cr |
| #5 | HDFC Mutual Fund | +24.77% | +10.10% | 1.09 | 1.10% | ₹1,997 Cr |
| #6 | Mirae Asset Mutual Fund | +24.42% | +27.89% | 1.28 | - | ₹3,458 Cr |
| #7 | UTI Mutual Fund | +23.89% | +22.00% | 1.31 | 1.35% | ₹1,399 Cr |
| #8 | ICICI Prudential Mutual Fund | +22.73% | +10.29% | 0.95 | 2.08% | ₹3,926 Cr |
| #22 | ITI Pharma and Healthcare FundCurrent Fund ITI Mutual Fund | +20.53% | +16.80% | 1.01 | 0.89% | ₹266 Cr |
Costs and fund facts
- Expense ratio (stated maximum)
- Direct 0.89% · Regular 2.59%
- Exit load
- If redeemed/Switched out on or before 3 Months from the date of allotment; Exit Load is 0.50% Exit Load after completion of 3 months - NIL
- Fund size (all plans)
- ₹266 CrAverage, quarter to September 2026
- Benchmark
- NIFTY HEALTHCARE INDEX TRI
- Allotment date
- 8 November 2021Scheme document
- Type
- An open ended Equity scheme investing in Pharma and Healthcare
- AMFI scheme code
- 149268
Fund managers (2)
- Animesh Singh
- Nilay Dalal
How each manager has done since taking over: fund manager scorecard.
Investment objective
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
From the scheme summary document filed with AMFI.
SIP calculator
A monthly SIP replayed on this fund's actual daily NAVs: what it would be worth today.
About this fund
ITI Pharma and Healthcare Fund Direct Growth is a mutual fund scheme from ITI Mutual Fund, listed by AMFI under “Equity Scheme - Sectoral/ Thematic”. This page covers the Direct plan with the Growth option. Its NAV was ₹20.5606 on 13 November 2026. It returned 16.80% over 1 year, 20.53% a year over 3 years and 15.45% a year over 5 years, measured from NAVs (3- and 5-year figures are annualised). Its benchmark, NIFTY HEALTHCARE INDEX TRI, returned 28.05% a year over 3 years. Its 3-year return ranks #22 of 142 Direct Growth plans in the same AMFI category. Q-Score: 83 out of 100, rated only against funds in the same category. The fund house rates its risk as “Very High risk” on the SEBI riskometer. Its average assets under management were ₹266 Cr across all plans for the quarter ending September 2026, as reported to AMFI. Its scheme summary document states a maximum expense ratio (TER) of 0.89% a year for the Direct plan. Managed by Animesh Singh and Nilay Dalal. Its scheme summary document gives the allotment date as 8 November 2021.
Figures are calculated from AMFI NAVs and index data, not taken from fund factsheets. Methodology. Past performance is not a guide to future returns.